Table 2.
Recruitment of cases with Guillain-Barré syndrome and coverage with pandemic influenza A (H1N1) vaccination by country
| Netherlands | Sweden | UK* | Denmark† | France | Pooled | |
|---|---|---|---|---|---|---|
| Brand used | Focetria (Pandemrix in children) | Pandemrix | Pandemrix (Celvapan, Focetria) | Pandemrix | Pandemrix (Celvapan, Focetria, Panenza) | — |
| Vaccination coverage (%)‡ | 33 | 62 | 8 | 6 | 7-8 | |
| Approximate source population (million) | 16 | 9.4 | 3.5 | 5.5 | 10-20 | 49.4 |
| Expected No of cases in study period§ | 100 | 59 | 22 | 34 | 62-25 | 299 |
| No of cases recruited | 33 | 26 | 34 | 24 | 37 | 154 |
| No of cases with ≥1 control | 25 | 18 | 30 | 24 | 7 | 104 |
| Total No of controls | 227 | 60 | 300 | 590 | 21 | 1198 |
| Total study population | 252 | 78 | 330 | 614 | 28 | 1302 |
| Characteristics of cases (No (%) unless stated otherwise) | ||||||
| Mean (SD) age (years) | 46 (23) | 55 (20) | 48 (23) | 48 (19) | 61 (16) | 50 (22) |
| Age ≤18 | 4 (16) | 0 | 4 (13) | 1 (4) | 0 | 9 (9) |
| Age 19-59 | 13 (52) | 9 (50) | 16 (53) | 16 (67) | 3 (43) | 57 (55) |
| Age ≥60 | 8 (32) | 9 (50) | 10 (33) | 7 (29) | 4 (57) | 38 (37) |
| Male | 14 (56) | 13 (73) | 17 (57) | 14 (57) | 4 (58) | 62 (60) |
| Brighton Collaboration case classification: | ||||||
| Level 1 | 10 (40) | 11 (61) | 0 | 7 (29) | 4 (57) | 32 (31) |
| Level 2 | 10 (40) | 3 (17) | 0 | 8 (33) | 2 (29) | 23 (22) |
| Level 3 | 3 (12) | 4 (22) | 0 | 3 (13) | 0 | 10 (10) |
| Neurologist confirmed but not level 1-3 | 2 (8) | 0 | 30 (100) | 6 (25) | 1 (14) | 39 (38) |
*UK stopped recruitment of cases and controls for case-control study on 2 Feb 2010.
†Register from which cases identified in Denmark ran until end of December 2009.
‡Based on VENICE data.
§Based on 1.5 per 100 000 person years (IR) and 5 month study period: IR*source population*5/12.